Henderson B W
Department of Radiation Medicine, Roswell Park Memorial Institute, Buffalo, New York.
Photodermatol. 1989 Oct;6(5):200-11.
With the advent of Phase III clinical trials, photodynamic therapy of solid tumors is about to gain respectability within the field of cancer therapy. This treatment modality uses visible light to activate tumor-localizing photosensitizers, and causes tissue destruction by generating highly cytotoxic molecular oxygen species. The almost universal tumor response achievable, mild general toxicity, and repeatability of treatment without loss of effectiveness account for its application in a wide variety of human neoplasms. A decade of basic and preclinical research has laid a solid foundation of knowledge of the mechanisms of the photodynamic effect, both on the cellular and tissue levels. Although open questions remain, these efforts have provided the rationale for new directions of development, such as the design of new photosensitizers and improved light sources. This report describes the events involved in photodynamic tumor destruction, emphasizing possible ways to improve this therapy in the future.
随着III期临床试验的出现，实体肿瘤的光动力疗法即将在癌症治疗领域获得认可。这种治疗方式利用可见光激活肿瘤定位光敏剂，并通过产生高细胞毒性的分子氧物种来导致组织破坏。几乎可以实现的普遍肿瘤反应、轻微的全身毒性以及治疗的可重复性且不丧失有效性，这些因素使得它在多种人类肿瘤中得到应用。十年的基础研究和临床前研究在细胞和组织水平上为光动力效应机制的知识奠定了坚实基础。尽管仍存在一些未解决的问题，但这些努力为新的发展方向提供了理论依据，例如新型光敏剂的设计和改进的光源。本报告描述了光动力肿瘤破坏所涉及的事件，强调了未来改进这种疗法的可能途径。
